Pharmacological options in the treatment of benign prostatic hyperplasia.
Kenny
B
B
Department of Discovery Biology, Pfizer Central Research, Sandwich, Kent, UK.
Ballard
S
S
Blagg
J
J
Fox
D
D
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001667:Binding, Competitive; D018849:Controlled Clinical Trials as Topic; D016232:Endothelins / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000378:metabolism; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D013329:Structure-Activity Relationship
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D016232:Endothelins; D004791:Enzyme Inhibitors; D011942:Receptors, Adrenergic, alpha